C763DZZ
Nonimaging Nuclear Medicine Assay Blood to None with None, Indium 111 (In-111) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | C Nuclear Medicine |
| Body System | 7 Lymphatic and Hematologic System |
| Operation | 6 Nonimaging Nuclear Medicine Assay |
| Body Part | 3 Blood |
| Approach | D Indium 111 (In-111) |
| Device | Z None |
| Qualifier | Z None |
Operation Definition
Introduction of radioactive materials into the body for the study of body fluids and blood elements, by the detection of radioactive emissions
Procedure Overview
This family describes nonimaging nuclear medicine assays performed on the lymphatic and hematologic system, laboratory-based tests that use radioactive tracers to measure quantities within blood or other body fluids rather than to create a picture. Examples include red blood cell volume and survival studies, plasma volume determinations, and Schilling tests for vitamin B12 absorption, each of which introduces a small radioactive marker and then analyzes samples drawn afterward for their radioactivity levels. These studies help physicians work up conditions such as unexplained anemia, polycythemia, or malabsorption by quantifying how the body handles specific blood components over time, information that a standard blood count alone cannot provide.
Anatomy & Axis Detail
Blood
Nonimaging nuclear medicine assay of blood involves in vitro or in vivo radioisotopic laboratory analysis of a blood sample, most classically red cell mass and plasma volume studies, red cell survival and sequestration studies, or Schilling-type absorption testing, rather than any imaging acquisition. A measured quantity of radiolabeled cells or tracer is introduced, and serial blood samples are drawn and counted in a well counter to quantify a physiologic parameter such as total blood volume, red cell lifespan, or sites of abnormal red cell destruction. These studies are used to evaluate polycythemia, unexplained anemia, hemolysis, and splenic sequestration when clinical and standard laboratory data are insufficient to establish a mechanism. Because the assay measures activity in withdrawn blood rather than producing an image, it is coded distinctly from planar or tomographic lymphatic and hematologic studies despite using similar tracers.
Radionuclide: Indium 111 (In-111)
Indium 111 (In-111) designates studies using this radionuclide, commonly bound to white blood cells or specific peptides for infection imaging, tumor localization, or cerebrospinal fluid flow studies. It has a longer half-life than Technetium 99m, making it suited to delayed imaging over days. This value distinguishes such studies from those using shorter-lived isotopes like Tc-99m or positron-emitting tracers such as Fluorine 18.
Coding & Documentation
A coder should look for documentation showing that radioactive material was introduced into the patient and that subsequent laboratory analysis of blood or other fluid samples, not camera-based imaging, produced the diagnostic result. The nuclear medicine report should specify the substance measured, such as red cell mass or plasma volume, and the fact that quantification came from counting radioactivity in withdrawn specimens. A frequent mistake is confusing these assay procedures with imaging studies that happen to use similar tracers, or failing to recognize that a multi-step protocol, such as a Schilling test with two phases, is still captured by a single root operation reflecting the introduction and subsequent laboratory measurement.
Commonly Confused With
This family is easily confused with Nonimaging Nuclear Medicine Probe procedures, since both avoid producing an image, but a probe study measures emissions directly from the patient's body while an assay measures radioactivity in samples removed from the body. It also overlaps conceptually with routine hematology laboratory testing, but ordinary blood counts and chemistry panels do not involve introducing radioactive tracers and are coded outside the nuclear medicine section entirely. The key distinction is always the presence of an administered radioactive substance analyzed through specimen counting rather than routine laboratory chemistry.